CN102942578B - Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin - Google Patents

Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin Download PDF

Info

Publication number
CN102942578B
CN102942578B CN201210321086.9A CN201210321086A CN102942578B CN 102942578 B CN102942578 B CN 102942578B CN 201210321086 A CN201210321086 A CN 201210321086A CN 102942578 B CN102942578 B CN 102942578B
Authority
CN
China
Prior art keywords
oxacephalosporin
formula
preparation
compound
ammonium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210321086.9A
Other languages
Chinese (zh)
Other versions
CN102942578A (en
Inventor
王海平
池骋
夏俊
池正明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Dongbang Pharmaceutical Co., Ltd.
Original Assignee
ZHEJIANG DONGBANG PHARMACEUTICAL CO Ltd
SHANGHAI YOUSHOU MEDICAL TECHNOLOGY DEVELOPMENT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG DONGBANG PHARMACEUTICAL CO Ltd, SHANGHAI YOUSHOU MEDICAL TECHNOLOGY DEVELOPMENT Co Ltd filed Critical ZHEJIANG DONGBANG PHARMACEUTICAL CO Ltd
Priority to CN201210321086.9A priority Critical patent/CN102942578B/en
Publication of CN102942578A publication Critical patent/CN102942578A/en
Application granted granted Critical
Publication of CN102942578B publication Critical patent/CN102942578B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention relates to the technical field of a synthesis method of 1-oxacephalosporin-3-epoxymethylene derivatives as a synthetic intermediate of 1-oxacephalosporin for resisting microbes and especially relates to a preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives shown in the formula (I). The preparation method is characterized in that a 1-oxacephalosporin-3-methylene derivative shown in the formula (II) is efficiently and selectively epoxidized into a 1-oxacephalosporin-3-epoxymethylene derivative by hydrogen peroxide in the presence of a catalyst. The 1-oxacephalosporin-3-epoxymethylene derivative and a derivative of a mercaptotetrazole alkali metal salt shown in the formula (III) undergo a reaction and the reaction products are dehydrated under acidic conditions to form a corresponding 1-oxacephalosporin intermediate shown in the formula (IV). The preparation method has the advantages that a halogen addition reaction is avoided; the easily available catalyst is used; a clean and environmentally friendly oxygen source is used; a reaction process is not carried out at a low temperature; equipment corrosion caused by halogens in industrial production is avoided; an investment of expensive special-purpose equipment is reduced; a risk generation rate is greatly reduced; and 1-oxacephalosporin preparation processes are simple and can be operated easily. Therefore, the preparation method has large competitiveness in industrial production.

Description

The preparation method of 1-oxacephalosporin-3-epoxy methylene derivatives and the application in the preparation of oxygen cephalo thereof
Technical field
The present invention relates to a kind of synthetic synthetic method technical field with intermediate 1-oxacephalosporin-3-epoxy methylene derivatives of antimicrobial 1-oxacephalosporin that can be used as.
Background technology
1-oxacephalosporin as latamoxef (Latamoxef) or flomoxef (Flomoxef) be the novel Broad spectrum antibiotics of a class, it has good anti-microbial activity to multiple Gram-negative bacteria, effect is stronger 4 ~ 16 times than general cynnematin.Because the synthetic difficulty of such oxygen cephalo is quite large, although investigator is numerous, the actual factory producing that can realize is very few.
The method of preparing at present 1-oxacephalosporin substantially all be take 1-oxacephalosporin-3-chloromethyl derivatives as intermediate carries out, and is shown below:
Synthesizing at Tetrahedron Letter 1980,21 of 1-oxacephalosporin-3-chloromethyl derivatives, 351-354 and US4604460 all have report its, be all to prepare by the method as shown in following equation,
The logical chlorine of 1-oxacephalosporin-3-methylene derivatives (being formula II) obtains two chlorine compounds of two key additions, and then eliminates tertiary chlorine by alkalescence, obtains 1-oxacephalosporin-3-chloromethyl derivatives.In experiment, find, the free radical reaction of the two keys of chlorine addition need to could be controlled optionally addition on two keys under utmost point low reaction temperatures, and the position free radical substitution reaction of unlikely generation allyl group, and when removing tertiary chlorine, also need very low temperature, because eliminating hydrochloric acid, dechlorination to use the highly basic such as DBU or lithium methoxide, when temperature of reaction, chloromethyl derivative will be destroyed during higher than-20 ℃, therefore this route requires to use expensive special introduce chlorine gas to make reaction equipment and extremely low temperature of reaction on producing, and must there be the various safeguard procedures of logical chlorine, these restrictions are very disadvantageous for the industrial applications of this route.
The method of preparing 1-oxacephalosporin from 1-oxacephalosporin-3-epoxy methylene derivatives there is not yet report widely, and reason may be the more difficult preparation of 1-oxacephalosporin-3-epoxy methylene derivatives.US4443598 has described and has utilized in bromine addition 1-oxacephalosporin-3-methylene derivatives process; existence due to water; two key adducts of generating portion hypobromous acid (HOBr); and then under existing, salt of wormwood obtains epoxide; whole process yield is low; and need to use the halogens such as bromine, and be unfavorable for environment protection, also cannot be truly for 1-oxacephalosporin industrial production.
Summary of the invention
The object of the invention is to develop the feasible preparation 1-oxacephalosporin-3-epoxy methylene derivatives of industrial production ( formula I) method, synthetic for 1-oxacephalosporin, solves many defects that existing synthetic route is used 1-oxacephalosporin-3-chloromethyl derivatives to exist, and makes the preparation of 1-oxacephalosporin become simple.
Through a large amount of experimental studies, the present inventor finds, the clean oxygen source hydrogen peroxide of use can be in the situation that catalyzer exists, and efficient selective ground epoxidation 1-oxacephalosporin-3-methylene derivatives, obtains 1-oxacephalosporin-3-epoxy methylene derivatives.In the substantially immovable situation of reaction system, this epoxide can successfully react with mercapto tetrazole an alkali metal salt, makes corresponding 1-oxacephalosporin intermediate.
The concrete technical scheme that the present invention takes is as follows:
1-oxacephalosporin-3-epoxy methylene derivatives ( formula I) preparation method, its step is included under the effect of catalyzer, 1-oxacephalosporin-3-methylene derivatives ( formula II) and hydrogen peroxide (H 2o 2) initial ring oxidizing reaction, generation 1-oxacephalosporin-3-epoxy methylene derivatives ( formula I)
Wherein, R 1for phenyl, 4-aminomethyl phenyl, benzyl, 4-cyano-phenyl or 4-p-methoxy-phenyl, R 2for hydrogen or methoxyl group, R 3for carboxyl-protecting group; Catalyzer is TS-1 molecular sieve or assorted many wolframic acids quaternary ammonium salt, and said quaternary ammonium salt cationic is: tetradecyl trimethyl ammonium, cetyl pyridinium base ammonium, cetyltrimethyl ammonium, octadecyl trimethyl ammonium, octadecyl dimethyl benzyl ammonium, tetrapropyl ammonium, TBuA, benzyl triethyl ammonium ammonium, methyl triethyl ammonium, two certain herbaceous plants with big flowers alkyl dimethyl ammonium or tricaprylmethylammonium.
Above-mentioned R 1representative be conventional acyl residue in cepham rhzomorph chemical field in fact; they can be the acyl groups that can generate the 7-position side chain of target Antibiotique composition; also can be in this compound synthetic, to serve as the acyl group of amino protecting group, be preferably phenyl, 4-aminomethyl phenyl or benzyl.
Above-mentioned R 3representative be a class carboxyl-protecting group in fact; comprise in cynnematin industry well-known can with carboxyl reaction or remove and do not cause other parts in this molecule anyly do not wish the carboxyl-protecting group that changes; be preferably wherein diphenyl-methyl, to nitrobenzyl (PNB), benzyl or to methoxy-benzyl, best is diphenyl-methyl.
Epoxidization reaction process catalyzer used is TS-1 molecular sieve or assorted many wolframic acids quaternary ammonium salt.TS-1 molecular sieve belongs to heterogeneous catalyst, and it is the effective catalyst of hydrogen peroxide epoxidation of olefins, is easy to remove by filter method after reaction finishes.Another kind of assorted many wolframic acids quaternary ammonium salt catalyst, has comprised heteropolyacid part and quaternary ammonium moiety, and preferably assorted many wolframic acids are partly [PO4 (WO3) 4]; Said quaternary ammonium salt cationic can be: tetradecyl trimethyl ammonium, cetyl pyridinium base ammonium, cetyltrimethyl ammonium, octadecyl trimethyl ammonium, octadecyl dimethyl benzyl ammonium, tetrapropyl ammonium, TBuA, benzyl triethyl ammonium ammonium, methyl triethyl ammonium, two certain herbaceous plants with big flowers alkyl dimethyl ammonium or tricaprylmethylammonium, be preferably cetyl pyridinium base ammonium, tetrapropyl ammonium or octadecyl dimethyl benzyl ammonium.Assorted many wolframic acids quaternary ammonium salt catalyst that the present invention is selected, in reaction process, can generate the active oxidation species that are dissolved in reaction system, whole reaction system is homogeneous phase, to give full play to catalysis epoxidation activity, and after reaction finishes, revert to again former assorted many wolframic acids quaternary ammonium salt catalyst, from reaction, separate out, be convenient to separation, reach the catalytic cycle object being shown below:
。
When using TS-1 molecular sieve as epoxidation catalyst, the consumption of TS-1 catalyzer be 1-oxacephalosporin-3-methylene derivatives ( formula II) the 0. 1wt% ~ 2.0wt% of weight, be preferably 0.4wt% ~ 0.8wt%.When using assorted many wolframic acids quaternary ammonium salt as epoxidation catalyst, the consumption of assorted many wolframic acids quaternary ammonium salt catalyst is 0. 005 ~ 0.1 times of 1-oxacephalosporin-3-methylene derivatives molar weight, is preferably 0.01 ~ 0.05 times.The consumption of hydrogen peroxide is 1.0 ~ 3.0 times of 1-oxacephalosporin-3-methylene derivatives molar weight, is preferably 1.2 ~ 1.8 times; The concentration of hydrogen peroxide is 5% ~ 90%, is preferably 25% ~ 30%.Concentration of hydrogen peroxide is too high, and the potential operating safety bringing can be larger, also can generate the by product of direct oxidation; Concentration is too low, and epoxidised efficiency can be affected, and 25% ~ 30% concentration range both can guarantee epoxidation speed, had guaranteed the safety of product and operating process simultaneously.The temperature of catalysis epoxidation is 0 ℃ ~ 50 ℃, is preferably 20 ℃ ~ 40 ℃, and more preferably 25 ℃ ~ 35 ℃, excess Temperature, can cause hydrogen peroxide self decomposed.
Epoxidation reaction solvent used is not particularly limited, as long as they do not produce harmful effect to this reaction, such as ether solvent, easily produces superoxide, is generally not used in the oxidizing reaction of hydrogen peroxide.The solvent that can select is as follows: C1 ~ C4 alcohol, as: methyl alcohol, ethanol etc.; C1 ~ C4 halogenated alkane, as: methylene dichloride, chloroform, ethylene dichloride etc.; C1 ~ C4 nitrile, as: acetonitrile or propionitrile etc.; C1 ~ C8 acetic ester, as ethyl acetate, methyl acetate etc.; C3 ~ C4 acid amides, as: dimethyl formamide, N,N-DIMETHYLACETAMIDE etc.; C6 ~ C10 contains benzene solvent, as: toluene, dimethylbenzene, chlorobenzene etc.Consider that a step is to react with mercapto tetrazole basic metal sodium salt subsequently, if select nitrile, acetate esters, amide solvent, reaction can produce unnecessary by product, increases post-processing difficulty, increases production cost.So preferred solvent is methyl alcohol, methylene dichloride.
If this reaction solvent is selected suitably, not need special separation and purification formula Icompound, can, according to after HPLC external standard method content, calculate the required the next step raw material adding and carry out subsequent reactions.
Another object of the present invention be to provide 1-oxacephalosporin-3-epoxy methylene derivatives ( formula I) application in 1-oxacephalosporin is synthetic, shown in following reaction formula:
Comprise the following steps: that epoxy group(ing) opening occurs for formula I epoxide and formula III mercapto tetrazole an alkali metal salt (M=Na or K), then under acidic conditions, dehydration can make corresponding 1-oxacephalosporin intermediate compound IV, wherein, and R 1, R 2and R 3definition described in above-mentioned formula I, R 4for methyl or 2-hydroxyethyl.
React an alkali metal salt used, can produce by mercapto tetrazole and sodium methylate (potassium) or sodium hydride (potassium) reaction in－situ, from production cost, consider, be preferably sodium salt.The consumption of mercapto tetrazole an alkali metal salt is formula icompound, according to 0.9 ~ 1.5 times of the molar weight of theoretical value calculating, is preferably 1.1 ~ 1.2 times.
Epoxy addition addition reaction solvent used is DMSO or C1 ~ C4 alcohol; C1 ~ C5 ether, as ether, methyl tertiary butyl ether, THF etc.; C3 ~ C4 acid amides, as DMF etc.; C1 ~ C4 chloroparaffin, as methylene dichloride etc., is preferably methyl alcohol.The acid used of dehydration reaction acidic conditions is hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid or methylsulfonic acid, tosic acid, is preferably phosphoric acid and polyphosphoric acid.The temperature of reaction is-20 ~ 80 ℃, and preferred temperature of epoxy addition addition stage is-10 ~ 10 ℃; The temperature of acidic conditions dehydration is preferably 30 ~ 50 ℃.
After epoxy addition addition reaction finishes, reaction system is first used phosphoric acid cancellation, then adds the warm 1-oxacephalosporin intermediate compound IV that obtains of polyphosphoric acid.
The reagent that the inventive method is used and raw material be commercially available obtaining all.
After finishing, each step reaction can carry out according to this area conventional treatment method.
Beneficial effect of the present invention: method use 1-oxacephalosporin-3-epoxy methylene derivatives of the present invention ( formula I) as intermediate, got around dexterously in the process of preparation 1-oxacephalosporin, must use the route of 1-oxacephalosporin-3-chloromethyl derivatives, can avoid the equipment corrosion causing due to logical halogen addition reaction in its industrial production, reduce the investment of expensive specific equipment, also greatly reduce dangerous odds; The required catalyzer of catalytic epoxidation is cheaply easy to get, and easy recovery, oxygen source hydrogen peroxide clean environment firendly used, reaction process does not need cold condition, make the preparation of 1-oxacephalosporin become simple, therefore when industrial production, there is larger competitive power.
embodiment:
Further explain by the following examples and explanation content of the present invention.In the present invention, the embodiment of the following stated is in order to set forth better the present invention, is not for limiting the scope of the invention.
Embodiment 1:
By Compound I I(R1, it is phenyl, R2 is hydrogen atom, R3 is diphenyl-methyl) stirring and dissolving 10 times amount methyl alcohol in, the TS-1 molecular sieve that adds Compound I I weight 0.8% under normal temperature (25 ℃), control under uniform temp and drip 1.8 times of 30% aqueous hydrogen peroxide solution of Compound I I molar weight, TLC detection reaction is complete, filters and removes TS-1 molecular sieve catalyst, reaction solution is concentrated into dry, the about 90%(HPLC external standard method of yield).Residual solid is dissolved with methylene dichloride, by a small amount of hypo solution washing, organic layer evaporate to dryness, residual solid ethyl acetate: normal heptane (4:1) recrystallization obtains off-white color Compound I (R1 is phenyl, and R2 is hydrogen atom, and R3 is diphenyl-methyl).Yield 61%. 1H-NMR(300MHz,?CDCl 3)：δ?8.45?(brs,?1H),?7.72~7.94?(m,?2H),?7.13~7.60?(m,?13H),?6.92?(s,?1H),?5.45?(s,?1H),?5.10?(d,?1H),?4.33?(s,?1H),?(3.42,?4.13)?(dd,?2H),?(2.70,?3.06)(dd,?2H)。
Embodiment 2:
By Compound I I(R1, be phenyl, R2 is hydrogen atom, and R3 is diphenyl-methyl) stirring and dissolving in 10 times of amount methyl alcohol, under normal temperature (25 ℃), add [π-the C of 0.01 times of Compound I I molar weight 5h 5nC 16h 33] 3[PO 4(WO 3) 4] catalyzer, control and at this temperature, drip 1.2 times of 30% aqueous hydrogen peroxide solution of Compound I I molar weight, TLC detection reaction is complete, filter and remove assorted many wolframic acids quaternary ammonium salt catalyst of separating out, reaction solution is concentrated into dry Compound I, and (R1 is phenyl, R2 is hydrogen atom, and R3 is diphenyl-methyl), the about 95%(HPLC of yield).Reaction product does not need to be further purified, and can be directly used in the next step.
Embodiment 3:
By Compound I I(R1, be phenyl, R2 is hydrogen atom, and R3 is diphenyl-methyl) stirring and dissolving in 10 times of amount methylene dichloride, under normal temperature (25 ℃), add [the C of 0.05 times of Compound I I molar weight 18h 37n (CH 2ph) (CH 3) 2] 3[PO 4(WO 3) 4] catalyzer, control and at this temperature, drip 1.2 times of 30% aqueous hydrogen peroxide solution of Compound I I molar weight, TLC detection reaction is complete, filter and remove assorted many wolframic acids quaternary ammonium salt catalyst of separating out, reaction solution is concentrated into dry Compound I, and (R1 is phenyl, R2 is hydrogen atom, and R3 is diphenyl-methyl), the about 91%(HPLC of yield).
Embodiment 4 ~ 9:
Reaction is used solvent to be the methyl alcohol of 10 times of amounts of raw material, and temperature of reaction is 25 ℃, and the concentration of hydrogen peroxide used is 30%, and consumption is 1.5 times of feed molar amount.Specific experiment operation is with above embodiment.The concrete raw material of its result and use etc. sees the following form 1:
Table 1:
。
Embodiment 10:
By above-described embodiment 2 gained Compound I, (R1 is phenyl, R2 is hydrogen atom, R3 is diphenyl-methyl) stirring and dissolving 10 times amount methyl alcohol in, be cooled to-10 ℃, add the mercapto tetrazole sodium salt (R4 is methyl) of theoretical molar amount 1.1eq, continue stirring reaction to TLC monitor showing Compound I and transform completely, add a little phosphoric acid cancellation reaction, and add equivalent polyphosphoric acid, and being warmed to 40 ℃, TLC monitor showing intermediates disappears and generates new point.Reaction solution is through neutralization, extraction, concentrated compound IV (R1 is phenyl, and R2 is hydrogen atom, and R3 is diphenyl-methyl, and R4 is methyl), the yield 83% of obtaining.Fusing point: 201 ~ 205 ℃. 1H-NMR(300MHz,?d 6-DMSO)：δ?7.95?(brs,?1H),?7.15~7.92?(m,?15H),?6.95?(s,?1H),?5.15?(s,?1H),?4.95?(d,?1H),?4.59?(s,?2H),?4.23?(s,?2H),?3.79?(s,?3H)。
Embodiment 11 ~ 17:
It can be the Compound I that separation obtains that raw material is used in reaction, or in above-described embodiment 1 ~ 9, the concentrated Compound I obtaining is directly carried out the next step; Solvent for use is the methyl alcohol of 10 times of amounts of raw material, and ring-opening reaction temperature is-10 ℃; Specific experiment operation is with above embodiment 10.The concrete raw material of its result and use etc. sees the following form 2:
Table 2:
。

Claims (22)

  1. The preparation method of 1.1-oxacephalosporin-3-epoxy methylene derivatives (formula I), its step is included under the effect of catalyzer, 1-oxacephalosporin-3-methylene derivatives (formula II) and hydrogen peroxide (H 2o 2) initial ring oxidizing reaction, generate 1-oxacephalosporin-3-epoxy methylene derivatives (formula I)
    Wherein, R 1can be phenyl, 4-aminomethyl phenyl, benzyl, 4-cyano-phenyl or 4-p-methoxy-phenyl, R 2for hydrogen or methoxyl group, R 3for carboxyl-protecting group; Catalyzer is TS-1 molecular sieve or assorted many wolframic acids quaternary ammonium salt, and the positively charged ion of described quaternary ammonium salt can be: tetradecyl trimethyl ammonium, cetyl pyridinium base ammonium, cetyltrimethyl ammonium, octadecyl trimethyl ammonium, octadecyl dimethyl benzyl ammonium, tetrapropyl ammonium, TBuA, benzyl triethyl ammonium ammonium, methyl triethyl ammonium, two certain herbaceous plants with big flowers alkyl dimethyl ammonium or tricaprylmethylammonium.
  2. 2. the application of 1-oxacephalosporin-3-epoxy methylene derivatives according to claim 1 (formula I) in 1-oxacephalosporin is synthetic, is characterized in that reaction formula as follows:
    Comprise the following steps: the epoxide of formula I and the mercapto tetrazole an alkali metal salt of formula III (M=Na or K) initial ring oxygen compound opening, then under acidic conditions, dehydration can make corresponding 1-oxacephalosporin intermediate compound IV, wherein, and R 1, R 2and R 3definition described in above-mentioned formula I, R 4for methyl or 2-hydroxyethyl.
  3. 3. the preparation method of formula I compound according to claim 1, is characterized in that: R 1for phenyl, 4-aminomethyl phenyl or benzyl.
  4. 4. the preparation method of formula I compound according to claim 1, is characterized in that: R 3for diphenyl-methyl, to nitrobenzyl (PNB), benzyl or to methoxy-benzyl.
  5. 5. the preparation method of formula I compound according to claim 4, is characterized in that: R 3for diphenyl-methyl.
  6. 6. the preparation method of formula I compound according to claim 1, is characterized in that: in the assorted many wolframic acids quaternary ammonium salt of catalyzer, assorted many wolframic acids are partly [PO4 (WO3) 4]; Quaternary ammonium salt cationic is cetyl pyridinium base ammonium, tetrapropyl ammonium or octadecyl dimethyl benzyl ammonium.
  7. 7. the preparation method of formula I compound according to claim 1, is characterized in that: the consumption of TS-1 catalyzer is the 0.1wt%～2.0wt% of 1-oxacephalosporin-3-methylene derivatives weight.
  8. 8. the preparation method of formula I compound according to claim 7, is characterized in that: the consumption of TS-1 catalyzer is the 0.4wt%～0.8wt% of 1-oxacephalosporin-3-methylene derivatives weight.
  9. 9. the preparation method of formula I compound according to claim 1, is characterized in that: the consumption of assorted many wolframic acids quaternary ammonium salt catalyst is 0.005～0.1 times of 1-oxacephalosporin-3-methylene derivatives molar weight.
  10. 10. the preparation method of formula I compound according to claim 9, is characterized in that: the consumption of assorted many wolframic acids quaternary ammonium salt catalyst is 0.01～0.05 times of 1-oxacephalosporin-3-methylene derivatives molar weight.
  11. 11. preparation methods of formula I compound according to claim 1, is characterized in that: the consumption of hydrogen peroxide is 1.0～3.0 times of 1-oxacephalosporin-3-methylene derivatives molar weight; The concentration of hydrogen peroxide is 5%～90%.
  12. 12. according to the preparation method of formula I compound described in claim 11, it is characterized in that: the consumption of hydrogen peroxide is 1.2～1.8 times of 1-oxacephalosporin-3-methylene derivatives molar weight; The concentration of hydrogen peroxide is 25%～30%.
  13. 13. preparation methods of formula I compound according to claim 1, is characterized in that: the temperature of catalysis epoxidation is 0 ℃～50 ℃.
  14. 14. according to the preparation method of formula I compound described in claim 13, it is characterized in that: the temperature of catalysis epoxidation is 25 ℃～35 ℃.
  15. 15. application of formula I compound in 1-oxacephalosporin is synthetic according to claim 2, is characterized in that: the basic metal of mercapto tetrazole an alkali metal salt is M=Na.
  16. 16. application of formula I compound in 1-oxacephalosporin is synthetic according to claim 2, is characterized in that: the consumption of mercapto tetrazole an alkali metal salt is 0.9～1.5 times of formula I compound molar weight.
  17. 17. application in 1-oxacephalosporin is synthetic according to formula I compound described in claim 16, is characterized in that: the consumption of mercapto tetrazole an alkali metal salt is 1.1～1.2 times of formula I compound molar weight.
  18. 18. the application of formula I compound in 1-oxacephalosporin is synthetic according to claim 2, is characterized in that: the solvent that reacts used can be the alcohol of DMSO, C1～C4, the acid amides of the ether of C2～C5, C3～C4 or the chloroparaffin of C1～C4.
  19. 19. application in 1-oxacephalosporin is synthetic according to formula I compound described in claim 18, is characterized in that: the solvent that reacts used is methyl alcohol.
  20. 20. application of formula I compound in 1-oxacephalosporin is synthetic according to claim 2, is characterized in that: the described acidic conditions acid used of reaction is hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, methylsulfonic acid or tosic acid.
  21. 21. application in 1-oxacephalosporin is synthetic according to formula I compound described in claim 20, is characterized in that: the described acidic conditions acid used of reaction is phosphoric acid and polyphosphoric acid.
  22. 22. application of formula I compound in 1-oxacephalosporin is synthetic according to claim 2, is characterized in that: the temperature in epoxy addition addition stage is-10～10 ℃; The temperature of acidic conditions dehydration is 30～50 ℃.
CN201210321086.9A 2012-09-03 2012-09-03 Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin Active CN102942578B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210321086.9A CN102942578B (en) 2012-09-03 2012-09-03 Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210321086.9A CN102942578B (en) 2012-09-03 2012-09-03 Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin

Publications (2)

Publication Number Publication Date
CN102942578A CN102942578A (en) 2013-02-27
CN102942578B true CN102942578B (en) 2014-09-03

Family

ID=47725590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210321086.9A Active CN102942578B (en) 2012-09-03 2012-09-03 Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin

Country Status (1)

Country Link
CN (1) CN102942578B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325115A (en) * 2017-07-31 2017-11-07 山西千岫制药有限公司 A kind of preparation method of oxygen cephalosporin intermediate
CN110003242A (en) * 2019-04-23 2019-07-12 山西千岫制药有限公司 A kind of preparation method of Flomoxef acid contamination levels product

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613330A (en) * 2008-06-25 2009-12-30 中国科学院大连化学物理研究所 The method of preparing cyclohexene oxide through hydrogen peroxide epoxidation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613330A (en) * 2008-06-25 2009-12-30 中国科学院大连化学物理研究所 The method of preparing cyclohexene oxide through hydrogen peroxide epoxidation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
孙可可.磷钨、钼酸季铵盐催化双氧水环氧化环己烯合成环氧环己烷的研究.《中国优秀硕士学位论文全文数据库工程科技I辑》.2012,(第3期),第10-11、15页.
磷钨、钼酸季铵盐催化双氧水环氧化环己烯合成环氧环己烷的研究;孙可可;《中国优秀硕士学位论文全文数据库工程科技I辑》;20120331(第3期);第10-11、15页 *

Also Published As

Publication number Publication date
CN102942578A (en) 2013-02-27

Similar Documents

Publication Publication Date Title
SG187140A1 (en) Process for preparing aminobenzoylbenzofuran derivatives
CN112625043B (en) Synthetic method of ridciclovir intermediate triazinylamine derivative
CN102942578B (en) Preparation method of 1-oxacephalosporin-3-epoxymethylene derivatives and use of the 1-oxacephalosporin-3-epoxymethylene derivatives in preparation of 1-oxacephalosporin
Yu et al. NH4I‐Catalyzed Synthesis of Sulfonamides from Arylsufonylhydrazides and Amines
EP2817319B1 (en) Novel method for manufacturing of ciclesonide
CN102633801B (en) Method for preparing tebipenem ester
CN110590887B (en) Preparation method of phosphate
CN107311960A (en) The synthetic method of 1,2,3 diazosulfide class compound
CN108164514B (en) Preparation method of epoxiconazole
CN103951647B (en) A kind of xanthone compounds and preparation method thereof
CN104987325B (en) A kind of preparation method of voriconazole
CN115093339A (en) Synthetic method of L-glufosinate-ammonium intermediate
CN104844554A (en) Most effective process for base-free preparation of ketone intermediates usable for manufacture of nebivolol
CN104910209B (en) A kind of method for preparing tenofovir
CN105273045A (en) Synthesis and separation identification method for aragatroban related substances
CN108203455B (en) Method for preparing finasteride by deiodinating dihydrofinasteride iodide
CN111620889A (en) Preparation method of levofloxacin intermediate
CN106478538A (en) Chlorine propionyl spiral shell benzimidazole dihydrochloride hexamethylene and its synthesis and application
CN115873055B (en) Method for safely producing mopiravir intermediate
CN114315866B (en) Synthesis method of levamisole hydrochloride
CN103787969B (en) A kind of (1S)-1-phenyl-3,4-dihydro-2(1H) preparation method of-isoquinolinecarboxylic acid ester
CN109912466B (en) Method for recovering camphorsulfonic acid
CN113929684B (en) Meropenem intermediate and preparation method thereof
CN105218510B (en) A kind of preparation method of the chloromethyl piperonyl cyclonene of 2,2 difluoro 5
CN109456257B (en) Preparation method of high-yield 2-chloro-5-nitropyridine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20170320

Address after: 317016 Zhejiang chemical raw material base in the coastal area

Patentee after: Zhejiang Dongbang Pharmaceutical Co., Ltd.

Address before: 201318 Pudong New Area City, Zhou Zhou Zhou road, Shanghai, building 134, room 9, No. 337

Patentee before: Shanghai Youshou Medical Technology Development Co., Ltd.

Patentee before: Zhejiang Dongbang Pharmaceutical Co., Ltd.

TR01 Transfer of patent right